Prostate Cancer Clinical Trials

Find Prostate Cancer Clinical Trials Near You

Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people. Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group TransPRIDE is a research study that will help us find the normal levels of PSA in trans women and non-binary people with prostates. Researchers will ask 500 trans women and non-binary people with prostates to take part. They will need to be aged 40 or over. They will need to be on hormones or have had lower surgery. They will be called after 6 months to recheck their health. If a person has a high PSA, they may be sent for more tests. Knowing the normal PSA level for trans women and non-binary people will help doctors to find and treat their prostate cancer more quickly.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 100
Healthy Volunteers: t
View:

• • Aged \>40

‣ Transgender or non-binary (identify with a gender other than the one assigned at birth)

⁃ With a prostate

⁃ Fulfills at least one of the following 3 criteria with regards to gender-affirming medical care:

• Taking oestradiol for at least the last 3 months

∙ Taking anti-androgens for at least the last 3 months

∙ Ever had bilateral orchidectomy

⁃ Eligible for National Health Service (NHS) treatment

Locations
Other Locations
United Kingdom
Ambrose King Centre, Barts Health NHS Trust
RECRUITING
London
Time Frame
Start Date: 2026-04-04
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 500
Treatments
40-49 year olds
50-59 year olds
60-79 year olds
70+ year olds
Related Therapeutic Areas
Sponsors
Leads: Queen Mary University of London

This content was sourced from clinicaltrials.gov